Goldman Sachs Upgrading Humana

Goldman Sachs is out with a research report on Humana HUM and is upgrading shares to Buy. In the note, Goldman Sachs writes, "We think fiscal pressures will drive a bigger role for Medicare Advantage (MA) and ultimately a phasing-out of unmanaged ‘traditional' Medicare. Even without policy changes, MA is becoming the product choice for seniors as employer retiree coverage becomes increasing rare. Humana is most levered to MA among core names and the industry leader in terms of innovation, in our view." Shares of HUM lost $5.27 yesterday to close at $65.65.